Path: /therapeutics/bpc-157
Also Known As: Body Protection Compound-157, PL-10, PL-14736
Chemical Formula: C_62H_98N_16O_21
Sequence: Gly-Glu-Pro-Pro-Pro-Ala-Gly-Gly-Ser-Lys-Val-Pro-Gly
Molecular Weight: ~1419 Da
Path: /therapeutics/bpc-157
Also Known As: Body Protection Compound-157, PL-10, PL-14736
Chemical Formula: C_62H_98N_16O_21
Sequence: Gly-Glu-Pro-Pro-Pro-Ala-Gly-Gly-Ser-Lys-Val-Pro-Gly
Molecular Weight: ~1419 Da
Mechanism of Action
BPC-157 is a 15-amino acid pentadecapeptide derived from human gastric juice. It exhibits remarkable healing properties through multiple molecular pathways:
1. Anti-Inflammatory Effects
Downregulates pro-inflammatory cytokines: Reduces TNF-α, IL-1β, IL-6, and IL-8 expression[@milavic2020]
Gastrointestinal protection: Counteracts potential NSAID use for anti-inflammatory therapy
Tissue healing: May support recovery from any surgical interventions (DBS)
Anti-inflammatory: Systemic anti-inflammatory effects may complement other approaches
Neurotrophic potential: Theoretical support for neuronal health
Case For
Strong preclinical data for tissue protection and healing
Excellent safety profile in animal studies
Multiple mechanisms complement other therapeutic approaches
Easily accessible through compounding pharmacies
Case Against
No direct clinical evidence in tauopathies
Limited long-term safety data in humans
Not FDA-approved (research compound)
Quality control varies by manufacturer
Net Assessment
Priority: Consider — Low risk intervention with potential GI and tissue-protective benefits. The anti-inflammatory properties may provide modest synergistic effects with other therapies. Lacks direct evidence for CBS/PSP but has a favorable safety profile. Recommended as adjunct therapy, particularly if using NSAIDs or undergoing surgical procedures.
Confidence: Low-Moderate — Preclinical data strong, human data limited but encouraging for safety.
Research Gaps and Future Directions
CNS penetration studies: Determine BBB permeability and CNS concentrations
Neurodegeneration trials: No current trials in AD/PD/CBS/PSP
Combination protocols: Optimal stacking with other peptides/growth factors
Long-term safety: Extended use data in humans needed
References
[Alicic et al., J. Mol. Histol. (2014) (2014)](https://doi.org/10.1007/s10735-014-9582-1)
[Cicvarevic et al., Med Hypotheses (2014) (2014)](https://doi.org/10.1016/j.mehy.2014.06.018)
[Cetkovic et al., Period Biol (2012) (2012)](https://doi.org/10.18054/pb.2012.114.2689)
[Djakovic et al., Coll. Antropol. (2011) (2011)](https://doi.org/10.5671/ca.2011.35)
[Kang et al., Molecules (2018) (2018)](https://doi.org/10.3390/molecules23020498)
[Kljajic et al., J. Cell. Physiol. (2022) (2022)](https://doi.org/10.1002/jcp.30567)
[Kang et al., J. Orthop. Surg. (2019) (2019)](https://doi.org/10.1177/2309499019873516)
[Milavic et al., Inflammopharmacology (2020) (2020)](https://doi.org/10.1007/s10787-020-00784-5)
[Medvidovic et al., J. Physiol. (2021) (2021)](https://doi.org/10.1113/JP280980)
[Perovic et al., Free Radic. Biol. Med. (2019) (2019)](https://doi.org/10.1016/j.freeradbiomed.2019.01.028)
[Rashid et al., Int J Exp Pathol (2014) (2014)](https://doi.org/10.1111/iep.12071)
[Sikiric et al., J. Physiol. Pharmacol. (2018) (2018)](https://doi.org/10.1002/j.1469-7793.2001.0051d.x)
[Sikiric et al., Dig Dis Sci (2014) (2014)](https://doi.org/10.1007/s10620-014-3138-y)
[Sikiric et al., Gastroenterology (1994) (1994)](https://doi.org/10.1016/0016-5085(94)
[Sikiric et al., Eur J Pharmacol (2019) (2019)](https://doi.org/10.1016/j.ejphar.2019.04.041)
[Seiwerth et al., Curr Pharm Des (2021) (2021)](https://doi.org/10.2174/1381612827666210603121403)
[Sikiric et al., Brain Res. (2018) (2018)](https://doi.org/10.1016/j.brainres.2018.01.009)